References
- Fotherby K. Levonorgestrel - clinical pharmacokinetics. Clin. Pharmacokinet. 1995; 28: 203–15
- Guillebaud J. Advising women on which pill to take. Br. Med. J. 1995; 311: 1111–12
- Hammerstein J., Daume E., Simon A., Wider U. H., Schindler A. E., Back D. J., Ward S., Neiss A. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6β-hydroxycortisol. Contraception 1993; 47: 263–81
- Hammond G. L., Bocchinfuso W. P., Orava M., Smith C. L., van den Ende A., van Enk A. Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene. Contraception 1994; 50: 301–18
- Kuhnz W., Al-Yacoub G., Fuhrmeister A. Pharmacokinetics of LNG and EE after administration of LNG 150 μg and EE 30 μg. Contraception 1992; 46: 455–69
- Speroff L., DeCherney A., and the Advisory Board for the New Progestins. Evaluation of a new generation of oral contraceptives. Obstet. Gynecol. 1993; 81: 1034–47
- van der Vange N., Blankenstein M. A., Kloosterboer H. J., Haspels A. A., Thjssen J. H.H. Effects of Seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 1990; 41: 345–52
- Wiegratz I., Jung-Hoffmann C., Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception 1995; 51: 341–6
- Wilde M. I., Balfour J. A. Gestodene-a review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Drugs 1995; 50: 364–95